Nordic Nanovector ASA: R&D Day to be virtual via live webcast only

Nordic Nanovector ASA (OSE: NANOV), a clinical stage biotechnology company developing targeted radiopharmaceuticals to extend and improve the lives of patients with haematological cancers, provides an update on its planned R&D Day on Tuesday, 30 November 2021 starting at 14:00 CET/ 13:00 GMT/ 08:00 ET. The meeting, which was going to take place in person in Oslo, will now be held as a virtual event via live webcast only due to increased travel restrictions driven by the Omicron coronavirus variant.

Updated Agenda

14:00 - Welcome - Jan Egberts, Chairman

14:10 - Strategic reflections - Erik Skullerud, CEO

14:30 - Relapsed follicular lymphoma: evolving treatment algorithm and unmet medical need - Leo Gordon, MD, Northwestern University

14:55 - Navigating the NHL landscape with Betalutin - Pierre Dodion, MD, Incoming CMO

15:20 - Integrating targeted radioimmunotherapy in NHL care pathways - Marco Renoldi, MD, COO

15:35 - Break

15:45 - The CMC journey to BLA and launch readiness - Lars Nieba, PhD, CTO

16:00 - Nordic Nanovector pipeline: promising value-enhancing opportunities

• Leveraging our CD37 expertise - Maureen Deehan, PhD, Head of Corporate Development and Strategy and Jostein Dahle, PhD, CSO

16:40 - Concluding Remarks - Erik Skullerud, CEO

The webcast can be accessed from www.nordicnanovector.com in the section: Investors & Media and a recording will also be available on this page after the event.

The presentations will be available at www.nordicnanovector.com in the section: Investors & Media/Reports and Presentation/Presentations/2021 from 7:00am CET the same day.